Cancer Database Query Results

Scientific Papers found: Click to Expand⟱

1502-

SFN,

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

Review,

NA,

HDAC↓, AntiCan↑, DNMTs↓, hTERT/TERT↓, selectivity↑,

1501-

SFN,

The Inhibitory Effect of Sulforaphane on Bladder Cancer Cell Depends on GSH Depletion-Induced by Nrf2 Translocation

in-vitro,

CRC,

T24/HTB-9

2.5 µM vs >10uM

Dose↝, NRF2↑, GSH↓, eff↑,

1500-

SFN,

A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase

in-vitro,

Nor,

HEK293

in-vitro,

CRC,

HCT116

HDAC↓, P21↑, TOPflash↑,

1499-

SFN,

Sulforaphane suppresses metastasis of triple-negative breast cancer cells by targeting the RAF/MEK/ERK pathway

in-vitro,

BC,

TumCMig↓, TumCI↓, FAK↓, p‑MEK↓, p‑ERK↓,

1430-

SFN,

Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy

Trial,

BC,

250 μM GFN glucoraphanin

*HDAC3↓, HDAC↓, *toxicity↓,

1497-

SFN,

Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells

in-vitro,

Nor,

PrEC

in-vitro,

Pca,

LNCaP

15 µM SFN

in-vitro,

Pca,

PC3

HDAC↓, selectivity↑, TumCCA↑, Apoptosis↑, selectivity↑, H3↑, P21↑, selectivity↑,

1496-

SFN,

VitD3,

Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells

in-vitro,

CRC,

Caco-2

24 h to vitamin D (100 nmol L-1 ) either alone or in combination with SFN and trichostatin A (20 and 1 μmol L-1 , respectively)

eff↑, VDR↑, CYP11A1↓, HDAC↓,

1495-

SFN,

doxoR,

Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation

in-vivo,

Nor,

Rats

*CardioT↓, *NRF2↑, *eff↓, *ROS↓,

1494-

SFN,

doxoR,

Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model

in-vivo,

BC,

rats

in-vitro,

BC,

MCF-7

in-vitro,

Nor,

MCF10

CardioT↓, *GSH↑, *ROS↓, *NRF2↑, NRF2∅, HDAC↓, DNMTs↓, Casp3↑, ER-α36↓, Remission↑, eff↑, ROS↑, selectivity?,

1484-

SFN,

Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action

Review,

Var,

Review,

AD,

neuroP↑, AntiCan↑, NRF2↑, HDAC↓, eff↑, *ROS↓, neuroP↑, HDAC↓, *toxicity∅, BioAv↑, eff↓, cycD1/CCND1↓, CDK4↓, p‑RB1↓, Glycolysis↓, miR-30a-5p↑, TumCCA↑, TumCG↓, TumMeta↓, eff↑, ChemoSen↑, RadioS↑, CardioT↓, angioG↓, Hif1a↓, VEGF↓, *BioAv?, *Half-Life∅,

1483-

SFN,

Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment

in-vitro,

OS,

143B

0-10uM

in-vitro,

Nor,

HEK293

in-vivo,

OS,

25-50mg/kg

subcutaneous tumor-bearing nude mouse model

AntiCan↑, *toxicity∅, Ferroptosis↑, ROS↑, lipid-P↑, GSH↓, p62↑, SLC12A5↓, eff↓, GPx4↓, i-Iron↑, eff↓, MDA↑, TumVol↓, TumW↓, Ki-67↓, LC3B↑, *Weight∅,

1482-

SFN,

Sulforaphane induces apoptosis in T24 human urinary bladder cancer cells through a reactive oxygen species-mediated mitochondrial pathway: the involvement of endoplasmic reticulum stress and the Nrf2 signaling pathway

in-vitro,

Bladder,

T24/HTB-9

tumCV↓, Apoptosis↑, Cyt‑c↑, Bax:Bcl2↑, Casp9↑, Casp3↑, Casp8∅, cl‑PARP↑, ROS↑, MMP↓, eff↓, ER Stress↑, p‑NRF2↑, HO-1↑,

1481-

SFN,

docx,

Combination of Low-Dose Sulforaphane and Docetaxel on Mitochondrial Function and Metabolic Reprogramming in Prostate Cancer Cell Lines

in-vitro,

Pca,

LNCaP

6.55 µM SFN and 0.0675 µM DCT

Prostate cancer cell lines LNCaP and PC-3 were treated with individual IC50 doses of SFN and DCT and half-reduced IC50 values for the SFN:DCT combination.

in-vitro,

Pca,

PC3

1.1 µM SFN and 0.0005 µM DCT

ChemoSen↑, Casp3↑, ROS↑, Casp8↑, Cyt‑c↑, Glycolysis↓, GSH↓, GSH/GSSG↓, *toxicity↓,

1480-

SFN,

Sulforaphane Induces Cell Death Through G2/M Phase Arrest and Triggers Apoptosis in HCT 116 Human Colon Cancer Cells

in-vitro,

CRC,

HCT116

tumCV↓, TumCCA↑, Apoptosis↑, cycA1/CCNA1↑, CycB/CCNB1↑, CDC25↓, CDK1↓, ROS↑, eff↓, Cyt‑c↑, AIF↑, ER Stress↑,

1479-

SFN,

Sulforaphane triggers Sirtuin 3-mediated ferroptosis in colorectal cancer cells via activating the adenosine 5'-monophosphate (AMP)-activated protein kinase/ mechanistic target of rapamycin signaling pathway

in-vitro,

CRC,

HCT116

Ferroptosis↑, SIRT3↑, AMPK↑, mTOR↑, tumCV↓, ROS↑, MDA↑, Iron↑,

1478-

SFN,

acet,

Anti-inflammatory and anti-oxidant effects of combination between sulforaphane and acetaminophen in LPS-stimulated RAW 264.7 macrophage cells

in-vitro,

Nor,

eff↑, NO↓, iNOS↓, COX2↓, IL1β↓, ROS↓,

1477-

SFN,

Sulforaphane Induces Oxidative Stress and Death by p53-Independent Mechanism: Implication of Impaired Glutathione Recycling

in-vitro,

OS,

MG63

>10 μM

tumCV↓, Apoptosis↑, Casp3↑, ROS↑, GSR↓, GPx↓,

1476-

SFN,

PDT,

Enhancement of cytotoxic effect on human head and neck cancer cells by combination of photodynamic therapy and sulforaphane

in-vitro,

HNSCC,

eff↑, tumCV↓, ROS↑, eff↓, Casp↑,

1475-

SFN,

Form,

Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway

in-vitro,

Cerv,

HeLa

0-50 µM

TumCP↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↑,

1513-

SFN,

acetaz,

Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis

in-vitro,

BrCC,

H720

AZ, SFN, and AZ+SFN (10 μM, 20 μM, and 40 μM)

in-vivo,

BrCC,

AZ (20 mg/kg), SFN (40 mg/kg), and a combination of AZ (20 mg/kg) plus SFN (40 mg/kg), daily for two weeks

mice

in-vitro,

BrCC,

H727

eff↑, tumCV↓, Apoptosis↑, P21↑, PI3K↓, Akt↓, mTOR↓, 5HT↓, NRF2↑,

3947-

Shank,

Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPτ) induced neurotoxicity in Alzheimer's disease Drosophila model

in-vivo,

AD,

 (AD) Drosophila model

*OS↑, *antiOx↑, *ROS↓, *AChE↑, *neuroP↑, *memory↑,

3948-

Shank,

Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain

in-vivo,

AD,

150 mg/kg) for 3 months

Rats

*AChE↓, *ChAT↑, *NGF↑, *CDK5↓, *neuroP↑, *MDA↓,

3946-

Shank,

Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies

Review,

AD,

*neuroP↑, *cognitive↑, *AChE↓, *antiOx↑, *GSR↑, *SOD↑, *GSH↑, *Inflam↓, *ROS↓, *lipid-P↓, *cardioP↑,

3945-

Shank,

Novel insights on acetylcholinesterase inhibition by Convolvuluspluricaulis, scopolamine and their combination in zebrafish

in-vivo,

AD,

zebrafish

*AChE↓,

3944-

Shank,

Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies

Review,

AD,

*memory↑, *neuroP↑, *Inflam↓, *5HT↑,

3943-

Shank,

Protective Mechanisms of Nootropic Herb Shankhpushpi (Convolvulus pluricaulis) against Dementia: Network Pharmacology and Computational Approach

Review,

AD,

*neuroP↑, *memory↑, *other↝, *AChE↓, *MAOA↓, *MAOB↓, *TrkB↓, *tau↓, *APP↓, *ROS↓, *Mood↑,

4203-

SIL,

Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders

Review,

NA,

*MAPK↝, *AMPK↝, *NF-kB↓, *mTOR↝, *PI3K↝, *Akt↝, *BioAv↝, *memory↑, *BDNF↑, *TNF-α↓,

4204-

SIL,

Silymarin administration after cerebral ischemia improves survival of obese mice by increasing cortical BDNF and IGF1 levels

NA,

Stroke,

*OS↑, *BDNF↑, *IGF-1↑,

3326-

SIL,

Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway

in-vitro,

Liver,

HepG2

58.46

in-vitro,

Liver,

Hep3B

75.13 umol/L

*hepatoP↑, chemoPv↑, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, Hif1a↓, VEGF↓, angioG↓,

3313-

SIL,

Silymarin attenuates post-weaning bisphenol A-induced renal injury by suppressing ferroptosis and amyloidosis through Kim-1/Nrf2/HO-1 signaling modulation in male Wistar rats

in-vivo,

NA,

50-100 mg/kg/day

Twenty-four male Wistar rats

*NRF2↑, *HO-1↑, *creat↓, *BUN↓, *RenoP↑, *MDA↓, *TNF-α↓, *IL1β↓, *Cyt‑c↓, *Casp3↓, *GSTs↓, *GSH↑, *GPx4↑, *SOD↑, *GSR↓, *Ferroptosis↓,

3333-

SIL,

Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice

in-vivo,

NA,

mice

*GRP78/BiP↓, *XBP-1↓,

3332-

SIL,

Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2

in-vitro,

Lung,

A549

*antiOx↑, *hepatoP↑, MMP2↓, uPA↓, TIMP2↑,

3331-

SIL,

The clinical anti-inflammatory effects and underlying mechanisms of silymarin

Review,

NA,

*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,

3330-

SIL,

Mechanistic Insights into the Pharmacological Significance of Silymarin

Review,

Var,

*neuroP↑, *hepatoP↑, *cardioP↑, *antiOx↓, *NLRP3↓, *NAD↑, ROS↓, NLRP3↓, TumCMig↓, *COX2↓, *iNOS↓, *MPO↓, *AChE↓, *LDH↓, *Telomerase↓, *Fas↓,

3329-

SIL,

Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis)

in-vivo,

Nor,

rainbow trout

*NO↓, *MDA↓, *TAC↑, *Hif1a↓, *iNOS↓,

3328-

SIL,

Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB

in-vivo,

BPH,

injected testosterone (3 mg/kg/day, subcutaneously (s.c.)) for 2 weeks.

Rats

*NF-kB↓, *Hif1a↓, *PTEN↑, *Weight↓, *NO↓, *IL6↓, *IL8↓, *COX2↓, *iNOS↓,

3327-

SIL,

Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia

in-vitro,

Liver,

HepG2

SM at 0, 10, 20, and 40 mg/L for 8 h

MDR1↓, Hif1a↓, P-gp↓,

3325-

SIL,

Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury

in-vivo,

Nor,

Rats

*Inflam↓, *ROS↓, *Casp3↑, *Casp9↑, *Hif1a↓, *iNOS↓, *SOD↑, *MDA↓,

3324-

SIL,

Silymarin prevents NLRP3 inflammasome activation and protects against intracerebral hemorrhage

*ROS↓, *TAC↑, *NF-kB↓, *IL2↓, *NRF2↑, *HO-1↑, *neuroP↑, *Inflam↓, *NLRP3↓,

3323-

SIL,

Anticancer therapeutic potential of silibinin: current trends, scope and relevance

Review,

Var,

Inflam↓, angioG↓, antiOx↑, TumMeta↓, TumCP↓, TumCCA↑, TumCD↑, α-SMA↓, p‑Akt↓, p‑STAT3↓, COX2↓, IL6↓, MMP2↓, HIF-1↓, Snail↓, Slug↓, Zeb1↓, NF-kB↓, p‑EGFR↓, JAK2↓, PI3K↓, PD-L1↓, VEGF↓, CDK4↓, CDK2↓, cycD1/CCND1↓, E2Fs↓,

3322-

SIL,

Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression

in-vitro,

Lung,

A549

0, 5, 10 and 20 µg/mL) for 24 h

in-vitro,

Lung,

H1299

in-vitro,

Lung,

H460

HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, HDAC8↓, HATs↑, Zeb1↓, E-cadherin↑, TumCMig↓,

3321-

SIL,

Silymarin (Milk thistle)

Review,

AD,

*neuroP↝, *Dose↝, *Half-Life?, *BioAv↝, *cognitive↑, *Aβ↓, *Inflam↓, *OS↑, *memory↑,

3320-

SIL,

Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action

Review,

AD,

*hepatoP↑, *neuroP↑, *ROS↓, *β-Amyloid↓, *Inflam↓, *Aβ↓, *NF-kB↓, *TNF-α↓, *TNF-β↓, *iNOS↓, *NO↓, *COX2↓,

3319-

SIL,

Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms

Review,

AD,

Review,

Park,

Review,

Stroke,

*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,

3318-

SIL,

Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight

Review,

AD,

Review,

Park,

*hepatoP↑, *neuroP↑, *TLR4↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *memory↑, *cognitive↑, *NRF2↑, *HO-1↑, *ROS↓, *Akt↑, *mTOR↑, *SOD↑, *Catalase↑, *GSH↑, *IL10↑, *IL6↑, *NO↓, *MDA↓, *AChE↓, *MAPK↓, *BDNF↑,

3317-

SIL,

Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders

Review,

NA,

*neuroP↑,

3316-

SIL,

Chemo,

Silymarin Nanoparticles Counteract Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights into Mitochondrial Dysfunction and Nrf2/HO-1 Axis

Inflam↓, antiOx↓, neuroP↑, cognitive↑, NRF2↑, HO-1↑, memory↑, AChE↓, Casp3↓,

3315-

SIL,

Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats

in-vivo,

Nor,

rats

neuroP↑, *NRF2↑, *HO-1↑, *lipid-P↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *NF-kB↓, *TNF-α↓, *JNK↓, *Bcl-2↑, *BAX↑,

3314-

SIL,

Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review

Review,

NA,

*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,

3647-

SIL,

Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation

in-vivo,

NA,

One hundred and ten sows

*IL1β↓, *GutMicro↝, *Inflam↓,

Showing Research Papers: 5101 to 5150 of 5929
Prev Page 103 of 119 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5929

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

antiOx↓, 1, antiOx↑, 4, Catalase↑, 3, Ferroptosis↓, 1, GPx↑, 1, GPx4↑, 1, GSH↑, 7, GSR↓, 1, GSR↑, 1, GSTs↓, 1, HO-1↑, 5, lipid-P?, 1, lipid-P↓, 4, MDA↓, 6, MPO↓, 1, NRF2↑, 7, ROS↓, 14, SOD↑, 6, TAC↑, 2,

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1, AMPK↑, 1, AMPK↝, 1, BUN↓, 1, LDH↓, 1, NAD↑, 1,

Cell Death ⓘ

Akt↑, 1, Akt↝, 1, Apoptosis↓, 1, BAX↑, 1, Bcl-2↑, 1, Casp3↓, 1, Casp3↑, 1, Casp9↑, 1, Cyt‑c↓, 1, Fas↓, 1, Ferroptosis↓, 1, iNOS↓, 8, JNK↓, 1, p‑JNK↓, 1, MAPK↓, 3, MAPK↝, 1, necrosis↓, 1, p38↓, 1, p‑p38↓, 1, Telomerase↓, 1,

Transcription & Epigenetics ⓘ

other↝, 1,

Protein Folding & ER Stress ⓘ

GRP78/BiP↓, 1, XBP-1↓, 1,

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 2, HDAC3↓, 1, IGF-1↑, 1, mTOR↑, 1, mTOR↝, 1, OCT4↓, 1, PI3K↝, 1, PTEN↑, 1,

Migration ⓘ

5LO↓, 1, APP↓, 1, CDK5↓, 1,

Angiogenesis & Vasculature ⓘ

EGFR↓, 1, Hif1a↓, 3, NO↓, 4,

Barriers & Transport ⓘ

BBB?, 1, OATPs↓, 1,

Immune & Inflammatory Signaling ⓘ

COX2↓, 5, IFN-γ↓, 1, IL10↑, 1, IL1β↓, 4, IL2↓, 2, IL4↓, 2, IL6↓, 1, IL6↑, 1, IL8↓, 1, Inflam↓, 10, NF-kB↓, 9, PGE2↓, 1, TLR4↓, 2, TNF-α↓, 7, TNF-β↓, 1,

Synaptic & Neurotransmission ⓘ

5HT↑, 1, AChE↓, 7, AChE↑, 1, BChE↓, 1, BDNF↑, 3, ChAT↑, 1, MAOA↓, 1, NGF↑, 1, tau↓, 2, TrkB↓, 1,

Protein Aggregation ⓘ

Aβ↓, 3, MAOB↓, 1, NLRP3↓, 3, β-Amyloid↓, 1,

Drug Metabolism & Resistance ⓘ

BioAv?, 1, BioAv↝, 2, Dose↝, 1, eff↓, 1, Half-Life?, 1, Half-Life↑, 1, Half-Life∅, 1,

Clinical Biomarkers ⓘ

ALAT↓, 1, AST↓, 1, creat↓, 1, EGFR↓, 1, GutMicro↑, 1, GutMicro↝, 1, IL6↓, 1, IL6↑, 1, LDH↓, 1,

Functional Outcomes ⓘ

cardioP↑, 2, CardioT↓, 1, cognitive↑, 4, hepatoP↑, 7, memory↑, 7, Mood↑, 1, neuroP↑, 13, neuroP↝, 1, OS↑, 3, RenoP↑, 1, Strength↑, 1, toxicity↓, 2, toxicity∅, 2, Weight↓, 1, Weight∅, 1,
Total Targets: 125

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Cancer Database Query Results

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Synaptic & Neurotransmission ⓘ

Protein Aggregation ⓘ

Hormonal & Nuclear Receptors ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Synaptic & Neurotransmission ⓘ

Protein Aggregation ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page